Etiology and Pathophysiology

Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review

F. B. Seganfredo, C. A. Blume, M. Moehlecke, A. Giongo, D. S. Casagrande, J. V. N. Spolidoro, A. V. Padoin, B. D. Schaan and C. C. Mottin

1Medicine and Health Sciences Post-Graduate Program, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil, 2Post-Graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Instituto do Petróleo e dos Recursos Naturais, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil, 4Centro de Obesidade e Síndrome Metabólica, Hospital São Lucas da PUCRS, Porto Alegre, Brazil, 5Faculty of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil, and 6Faculty of Medicine and Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Received 11 December 2016; revised 14 February 2017; accepted 27 February 2017

Address for correspondence: FB Seganfredo, Medicine and Health Sciences Post-Graduate Program, Pontifícia Universidade Católica do Rio Grande do Sul, Av. Ipiranga, 6690 – Prédio 60 – Partenon – Porto Alegre, RS 90610-000, Brazil.
E-mail: fbseganfredo@gmail.com

Summary

Imbalances in the gut microbiota, the bacteria that inhabit the intestines, are central to the pathogenesis of obesity. This systematic review assesses the association between the gut microbiota and weight loss in overweight/obese adults and its potential manipulation as a target for treating obesity. This review identified 43 studies using the keywords ‘overweight’ or ‘obesity’ and ‘microbiota’ and related terms; among these studies, 17 used dietary interventions, 11 used bariatric surgery and 15 used microbiota manipulation. The studies differed in their methodologies as well as their intervention lengths. Restrictive diets decreased the microbiota abundance, correlated with nutrient deficiency rather than weight loss and generally reduced the butyrate producers Firmicutes, Lactobacillus sp. and Bifidobacterium sp. The impact of surgical intervention depended on the given technique and showed a similar effect on butyrate producers, in addition to increasing the presence of the Proteobacteria phylum, which is related to changes in the intestinal absorptive surface, pH and digestion time. Probiotics differed in strain and duration with diverse effects on the microbiota, and they tended to reduce body fat. Prebiotics had a bifidogenic effect and increased butyrate producers, likely due to cross-feeding interactions, contributing to the gut barrier and improving metabolic outcomes. All of the interventions under consideration had impacts on the gut microbiota, although they did not always correlate with weight loss. These results show that restrictive diets and bariatric surgery reduce microbial abundance and promote changes in microbial composition that could have long-term detrimental effects on the colon. In contrast, prebiotics might restore a healthy microbiome and reduce body fat.

Keywords: Bariatric surgery, microbiota, obesity, weight loss.

Abbreviations: BF, body fat; BIB, bilio-intestinal bypass; BMI, body mass index; BP, blood pressure; BW, body weight; CRC, colorectal cancer; DBP, diastolic blood pressure; DGGE, denaturing gradient gel electrophoresis; F/B ratio, Firmicutes to Bacteroidetes ratio; FBG, fasting blood glucose; FBI, fasting blood insulin; FISH, fluorescence in situ hybridization; GB, gastric banding; LSG, laparoscopic sleeve gastrectomy; NRCT, non-randomized clinical trial; qPCR, quantitative polymerase chain reaction; RCT, randomized clinical Trial; RoB, risk of bias [Cochrane Collaboration’s tool]; RoBANS, risk of bias assessment tool for nonrandomized studies; RYGB, Roux-en-Y gastric bypass; SBP, systolic blood pressure; SCFA, short-chain fatty acids; SD, standard deviation; TC, total cholesterol; TG, triglycerides; T2DM, type 2 diabetes mellitus; VBG, vertical banded gastroplasty; WC, waist circumference.
Introduction

Overweight and obesity, which are defined as excessive body fat accumulation (1), constitute a global epidemic. According to the World Health Organization, more than 1.9 billion adults were overweight in 2014, and of these, more than 600 million were obese (1). The obesity epidemic is related to several health-threatening diseases, such as arterial hypertension, type 2 diabetes mellitus [T2DM], dyslipidemia, coronary heart disease [CHD], stroke, asthma and arthritis, among others (2). Furthermore, this condition has important economic impacts, increasing medical costs for the treatment of related conditions and indirectly causing reduced productivity, disabilities and premature mortality (3).

Classically, obesity has been attributed to an excessive caloric intake along with a sedentary lifestyle (4). Other factors include genetic predisposition, increasing maternal age, sleep deprivation, endocrine disruptors, pharmaceutical iatrogenesis and epigenetics (5). More recently, the gut microbiota, which is made up of the collection of microorganisms that inhabits human intestines, has been implicated in the aetiology of obesity (6). These bacteria play an important role in physiological processes such as digestion and metabolism, and they are suggested to participate in obesity and metabolic disorder development because they are able to increase energy production from the diet, induce low-grade inflammation, regulate the fatty acid tissue composition and participate in appetite regulation through the gut-brain axis (7–10).

Many pre-clinical and clinical studies have related the gut microbiota to obesity. Animal data have shown that germ-free mice are resistant to obesity, and, upon the introduction of gut microbes, the animals are likely to increase their caloric uptake and develop fat deposition and insulin resistance (11,12). Furthermore, mice that were colonized with gut microbiota from obese mice harvested energy more efficiently and developed body fat more quickly (13). The sequencing of the gut microbiota using the 16S rRNA gene from the distal intestine in mice showed a distinct pattern between lean and obese animals with regards to the two major bacterial phyla, Firmicutes and Bacteroidetes. A proportional reduction in Bacteroidetes, along with an increase in Firmicutes, was observed in the obese population (14). Clinical studies also support the link between gut microbiota and obesity, and although the differences at the phylum level between lean and obese individuals are conflicting (15,16), other microbiota features have been suggested to interfere with weight responses to interventions (17,18). Thus, the association between microbiota and obesity exists, yet the causative versus consequential association and the magnitude of its contribution in humans, remains unclear.

Among the therapeutic options for addressing obesity, lifestyle modifications [diet, physical activity and behavioural therapy], pharmacological treatment and, for severe cases, surgical intervention are currently available. Lifestyle modifications alone promote a long-term weight loss of 5–10% of the original weight, although there is a tendency to regain 30–50% of the lost weight within the first year and the remaining weight during the second year (19). Pharmacological therapy can also promote modest weight loss, but the majority of drugs are limited due to side effects and a lack of compliance (20). Bariatricsurgery is currently the most effective option for the long-term treatment of severe obesity, promoting significant weight loss and mortality reduction (19). Despite its relative effectiveness, a significant number of patients experience poor weight-loss outcomes, and long-term weight regain can reach up to 75% (21,22). Therefore, further approaches are needed to overcome those issues and help patients to reduce and maintain a healthy weight. In that respect, gut microbiota manipulation might represent a novel target, as such an approach has been associated with sustainable weight loss (23).

Although the interplay between the gut microbiota and weight modifications in overweight and obese populations is currently a topic of interest, the interaction between these factors remains unclear. This systematic review assesses the association between the gut microbiota, weight-loss treatments and metabolic outcomes in overweight and obese adults and its potential manipulation as a target to treat obesity.

Methods

Protocol and registration

The protocol for this systematic review was registered on PROSPERO [CRD42015030003] and is fully available on the NIHR HTA program website [http://www.crd.york.ac.uk/PROSPERO].

Eligibility criteria

Studies were selected on the basis of the following criteria: observational studies with weight-loss interventions [quasi-experiments] or clinical trials that evaluated the gut microbiota of overweight or obese adults [≥18 years old]. Overweight and obesity were defined by body mass index [BMI] and were dependent on patient ethnicity. Weight-loss interventions included dietary interventions, bariatric surgery and pre-, pro- or symbiotics use.

Information sources

The following electronic databases were assessed, covering studies that were published up until November 2016:
MEDLINE [as accessed by PubMed], EMBASE, Science Direct, the Cochrane Central Register of Controlled Trials and LILACS. No date or language restriction was used while conducting this search.

Search strategy
No systematic reviews addressing this research question were available in MEDLINE [via PubMed] or the Cochrane Database at the beginning of this study. During this search, the terms for ‘obesity’ and ‘microbiota’ were obtained. To amplify our search strategy, no terms referring to interventions or controls were used. In December of 2015 [and updated in November 2016], database searches were performed using the terms ‘overweight’ or ‘obesity’ and ‘microbiota’ or ‘microbiome’ and related terms to obtain the broadest possible results [see Table S1: Search Strategy]. Potentially eligible papers were searched by screening reference lists and grey literature.

Study selection
Duplicates were manually identified and excluded. The articles were then analysed using the following two-step procedure. First, titles and abstracts that were retrieved from our literature search were independently analysed by two reviewers on the basis of inclusion/exclusion criteria. Then, all of the included articles were subjected to another analysis of their full text, and the eligible articles were identified. Disagreements were resolved by consensus-based discussion or by a third reviewer’s opinion. The agreement between the reviewers was assessed using Cohen’s kappa coefficient (24).

Data extraction and quality assessment
Two reviewers independently extracted data from each study using an extract table template. The extracted data were as follows: identification of the study, population description, study design, intervention details and outcomes. The primary outcome was a gut microbiota assessment (for total bacterial abundance, richness, alpha and beta diversity, and bacterial taxonomic composition [phylum, genus and species]). Secondary outcomes included anthropometric and clinical outcomes. A third reviewer assessed all of the studies for the completeness of their data extraction.

To assess the internal quality of the studies, the Cochrane Collaboration’s tool for assessing the risk of bias [RoB] was used for each randomized clinical trial [RCT] (25). The following areas were assessed: sequence generation, allocation concealment, the blinding of participants and personnel, the blinding of outcomes, incomplete outcome data, selective reporting and other bias. Each domain was graded as having a low, unclear or high RoB. For non-randomized studies [NRCTs], the Risk of Bias Assessment Tool for Nonrandomized Studies [RoBANS] was used (26). The RoBANS included an evaluation of the participant selection, confounding variables, measurements of exposures, blinding of outcomes, incomplete outcome data and selective reporting. The assessment of the RoB was made according to the RoBANS criteria, and each criterion was graded as having a low, unclear or high RoB.

Data synthesis and analysis
This review summarizes the available results from the literature about gut microbiota changes related to weight loss in obese and overweight populations. A narrative synthesis is presented.

Results
Literature search
Overall, we identified 7,311 records, and after excluding the duplicates and non-eligible titles, 43 original articles were included. A detailed flowchart showing the study selection process is presented in Fig. 1. The inter-rater agreement as calculated by Cohen’s kappa coefficient was 0.9. We classified studies based on intervention type as follows: (i) dietary; (ii) surgical and (iii) microbiota interventions [pre-, pro-, symbiotics]. The results are presented according to this classification.

General characteristics of the studies
The primary characteristics of the 43 included studies are described in Tables 1, 2 and 3. Seventeen of the studies evaluated dietary interventions, 11 involved surgery and 15 addressed specific therapeutics relating to the gut microbiota. Twenty-five [59%] of the included studies were published in the last 3 years. Distinct study designs were found, with 17 RCTs [40%], 15 NRCTs [35%], 8 quasi-experiments [20%] and 2 [5%] observational studies with cross-sectional designs. Geographically, 27 [65%] of the studies were performed in Europe, 10 [23%] in Asia and 5 [12%] in North America. Considering the patient selection, 25 [60%] studies had no gender limit, 11 [26%] included only women and 6 [14%] included only men. The ages of the included patients varied between 19 and 73 years old. The intervention type and setup were highly diverse among the trials, and the lengths of the interventions varied from 7 to 52 weeks, with a follow-up of up to 2 years. In all of the studies, a baseline assessment of the gut microbiota was obtained, and microbial composition changes were reported as outcomes.
Several molecular biology techniques were used to assess the gut microbiota, and some studies employed more than one approach. Five studies [11%] obtained a microbial community fingerprint using denaturing gradient gel electrophoresis [DGGE], 20 studies [46%] used at least one technique for targeted analysis (fluorescence in situ hybridization [FISH] using probes or group-specific real-time [quantitative] polymerase chain reaction [qPCR]), 13 studies [30%] performed metabarcoding 16S rRNA and 10 studies [23%] used metagenomics [shotgun sequencing]. Furthermore, one study used a computational analysis with the CASINO tool to predict microbial responses to dietary interventions, and others involved a HITChip analysis. In addition to assessing microbial richness and taxon profiles, some of the studies also reported microbiome measures of microbial metabolites and metabolic pathway expression that are beyond the scope of this review and therefore will not be discussed here. Further details on the molecular biology techniques used in the included studies are available in the supplementary material [See Table S2: Molecular Biology Techniques].

-Dietary interventions (Table 1 – Extended version available [see Table S3]):

This review included 17 studies on 11 different clinical trials that evaluated changes in gut microbiota following dietary interventions for weight loss. Of those trials, only five [45%] were RCTs (16,27–30). The number of patients included in each trial varied between 12 and 56 (average: 30, standard deviation [SD]: 16).

The composition of the gut microbiota was assessed through different techniques. Among the 11 included trials, 1 [9%] used only DNA targeted probes [FISH] (29), 3 [28%] used only metabarcoding 16S rRNA (16,28,31), 3 [28%] used only shotgun sequencing (27,32,33) and the 4 [36%] remaining trials combined techniques including the aforementioned ones, namely species-specific qPCR, DGGE and computational tools (18,30,34,35).

The first trial to evaluate the impact of a weight-loss intervention [low-fat vs. low-carbohydrate diets] on the gut microbiota was published in 2006, and the results showed no changes in bacterial abundance (16). However, marked interpersonal differences in the bacterial composition were described, in addition to percentage reductions in the frequency of the Firmicutes phylum along with increases in the Bacteroidetes phylum, which correlated with weight loss (16). Following this finding, several similar trials were performed.

Considering all of the included trials with dietary interventions, the total bacterial abundance was assessed in only six trials. Within those, five performed hypocaloric...
| Study Identification | Intervention Description | Follow-up | n | Sex | BMI | Marked inter-personal differences [70% unique to each person] with remarkably constancy. Both diets had no impact on bacterial abundance, [Firmicutes, [Bacteroidetes [correlated to percentage loss of body weight]]. |
|----------------------|--------------------------|-----------|---|-----|-----|--------------------------------------------------|
| Ley et al., 2006     | Fat-restricted versus carbohydrate-restricted diet | 52 weeks | 14 | 64% female | 30.0–43.0 | ↓ Firmicutes, ↑ Bacteroidetes [correlated to percentage loss of body weight]. |
| Duncan et al., 2007  | 3 to 7-day weight maintenance, 8-week diets [4 weeks each]: high protein low carb, ketogenic [LC] or high protein moderate carb [MC] | 9 weeks | 20 | 100% male | 35.4 ± 0.9 | ↓ Total bacterial count; No impact on Bacteroides or Clostridium cluster XIVa, IX or I, but subgroup Roseburia spp. and E. rectale subgroup of cluster XIVa and Bifidobacterium along with [carbohydrate intake]. |
| Duncan et al., 2008  | Weight-loss diets [LC and MC]: ↓ Total bacterial count; [Phylum: no impact on Bacteroidetes or Firmicutes abundance; however, ↓ Butyrate-producers within this phylum [Roseburia spp. + E. rectale group, belonging to Clostridium], especially with LC; ↓ Bifidobacterium. | 23 | 100% male | 20.0–44.0 | ↓ 5.8% BW, ↓ 13.3% BF |
| Russell et al., 2011 | 1-week weight maintenance, 6-week diets [3 weeks each]: resistant starch [RS] or non-starch polysaccharides [NSPs], 3-week hypocaloric diet with high protein and moderate carb [WL] | 10 weeks | 14 | 100% male | 39.3 ± 1.4 | ↓ Total bacterial count and ↓ Butyrate-producers Roseburia spp./E. rectale group [Lachnospiraceae], although no difference in F. prausnitzii [second main butyrate producer]. |
| Walker et al., 2011  | 1-week weight maintenance, 6-week diets [3 weeks each]: resistant starch [RS] or non-starch polysaccharides [NSPs], 3-week hypocaloric diet with high protein and moderate carb [WL] | | | | | |
| Salonen et al., 2014 | 1-week weight maintenance, 6-week diets [3 weeks each]: resistant starch [RS] or non-starch polysaccharides [NSPs], 3-week hypocaloric diet with high protein and moderate carb [WL] | | | | | |

(Continues)
| Study | Intervention | Population | Outcomes |
|-------|--------------|------------|----------|
| Cotillard et al., 2013 | 6-week hypocaloric, high protein, low carb, fibre enriched + 6-week weight maintenance -Subgroups based on bacterial diversity: low gene count [LGC] or high gene count [HGC] | - Subgroups based on bacterial diversity: low gene count [LGC] or high gene count [HGC] | - Baseline: LGC – 40%, HGC – 60%. Identification of 18 bacterial clusters, all more abundant in HGC individuals. -Post-intervention: ↑ bacterial diversity in LGC individuals. Species: ↓ E. rectale and Bifidobacterium spp. Majority of bacterial clusters suffered transient abundance changes during the intervention, but some changes that favor similarity of LGC to HGC were persistent. |
| Kong et al., 2013 | 6-week hypocaloric, high protein, low carb, fibre enriched + 6-week weight maintenance -Subgroups based on weight trajectory: A, B lost more weight during energy restriction; A continued loosing, B remained stable at stabilization. C lost less weight and rapidly regained. | 50 Sex: 84% female BMI: 27.0 – 38.0 | - Baseline: Lactobacillus/Louconostoc/Pedloccius group was most abundant in cluster C. No differences in C. leptum, C. coccoides, Bacteroides/Prevotella, Bifidobacterium, E. coli and F. prausnitzii were observed between groups. Month 12 [t0–12]: - A: ↓ 10% BW, ↓ 9.2% WC, ↓ 2.8% BF* - B: ↓ 5% BW, ↓ 6.3% BC, ↓ 1.9% BF* - C: ↓ 1.5% BW, ↓ 1.6% WC, ↓ 0.96% BF* |
| Shoaie et al., 2015 | Computational simulation of same intervention/patients as Cotillard et al. (2013) | 45 Sex: 83% female BMI: 33.2 ± 0.5 | - Baseline: dominance of E. coli, F. prausnitzii and 4 species associated with Clostridium, Bacteroides, Bifidobacteria and Lactobacillus. -Post-intervention: HGC individuals: ↑ B. thetaiotaomicron and ↓ L. reuteri and F. prausnitzii. LGC individuals: ↓ L. reuteri. |
| Dao et al., 2016 | 6-week hypocaloric, high protein, low carb, fibre enriched + 6-week weight maintenance-Subgroups: high or low A. muciniphila [HAK, LAK] | 49 Sex: 83% female BMI: 32.5 ± 1.0 | - Baseline: 70% of the species were more abundant in HAK. -Post-intervention: HAK group had ↓ A. muciniphila. Baseline: HAK versus LAK: HAK had lower waist-to-hip ratio and adipocyte size; -Post-intervention: no impact on BW between the groups. |
| Simoes et al., 2014 | Very-low-energy diet [VLED], high protein and low carb for 6 weeks, followed by weight-maintenance diet | 52 weeks | 16 Sex: 62% female BMI: 34.5 ± 2.6 | [Bacterial abundance, ↓ Bifidobacterium and Lactobacillus and ↑ Bacteroides: ↑ Roseburia/E. rectale group and ↑ Bifidobacterium and ↑ Ruminococcus. Gut microbiota changes were correlated to dietary intake and not to weight changes. High intra-individual similarity at all points. |
| Remely et al., 2015 | Weight maintenance, low fat and animal products, rich in fruits and vegetables | 16 weeks | 33 Sex: NA BMI: 46.6 ± 11.1 | [Bacterial abundance, ↓ FI ratio, ↑ Lactobacillus, Clostridium Cluster IV [↑ F. prausnitzii], A. muciniphila and Archaea; ↓ Clostridium Cluster XIV. |

(Continues)
| Study Identification | Intervention Description | Follow-up | n  | Description | Microbiota | Anthropometry |
|----------------------|--------------------------|-----------|----|-------------|------------|--------------|
| Remely et al., 2016  | Weight reduction diet [DACH recommendation] – insulin-dependent T2D versus obese controls versus lean controls | 16 weeks  | 56 | Sex: 57% female | BMI: 38.4 ± 5.1 [T2DM], 33.7 ± 4.2 [obese] | No differences in total bacteria between the groups or after intervention. F/B ratio was increased in T2D compared with controls, mainly due to Clostridiales and Lactobacillli. -T2D group: intervention caused ↑ relative abundance of F. prausnitzii and A. muciniphila. |
| Louis et al., 2016    | 52-week multidisciplinary weight-loss program, including very-low-calorie diet [VLED] fibre-enriched [3 m], gradual substitution to normal food [8 weeks], followed by weight maintenance. -Subgroups: persistent success [PS: n = 9] or regain/no success [NS: n = 7]. | 104 weeks | 16 | Sex: 56% female | BMI: 43.0 ± 7.0 | Baseline: Phylum: Bacteroidetes [68%] > Firmicutes [27%] > Proteobacteria [1.7%] > Actinobacteria [1.7%] > Verrucomicrobia [1.3%]. Genus: Bacteroides [55%] > Alistipes [8.0%] > Faecalibacterium [6.4%] > Eubacterium [5.4%]. High F/B ratio variability, without BMI correlation, although higher F/B ratio value in MetS patients. Predictors of success: Alistipes, Pseudoflavonifractor, Gordonibacter and Symbiobacterium. Alpha-diversity tended to be higher in patients with lower BMI at T0 but did not correlate to weight loss at T24. - Intervention: No impact on phylum level. VLED had impact on 56 genera, but only ↑ A. muciniphila remained stable. -Month 6 [t0–t6]: ↓ 20.9% BW, ↓ 18.4% WC -Month 24 [t0–t24]: ↓ 10% BW, ↓ 10.4% WC - PS versus NS: PS had higher relative weight loss during caloric restriction |
| Pataky et al., 2016   | 3-week hypocaloric, high-protein diet [starch free] | 6 weeks   | 15 | Sex: 26% female | BMI: 34.6 ± 2.2 | No significant impact in bacterial diversity. No impact on phylum composition; significant changes in lower-level taxa belonging to the Clostridiales [↑ relative abundance of Lachnospira, ↑ relative-abundance of Blautia, Bulyricoccus]; and changes in 10 OTUs [including ↓ in several OTUs of Bacteroides]. |
| Candela et al., 2016  | 3-week Ma-Pi diet [hypocaloric, fibre-enriched macrobiotic diet] versus control diet for T2DM versus normal weight controls | 3 weeks   | 53 | Sex: 50% female | BMI: 34.3 ± 6.5 [Ma-Pi], 32.1 ± 6.3 [control] | -T2DM comparison to normal weight controls: ↓ diversity, different UnFrac distances [PCoA], revealing segregation between the two groups [mainly due to ↑ relative abundance of Enterobacteriaceae, Collinsella and Streptococcus and ↓ relative abundance SCFA producers, such as Bacteroides, Prevotella, Lachnospira, Roseburia and Faecalibacterium] [0.4 times less]. -Ma-Pi versus control diet: Both diets tended to increase diversity [ns], both diets were effective in counteracting the ↓ Bacteroides, Dorea and Faecalibacterium seen T2D patients and ↑ Akkermansia above healthy controls abundance. Ma-Pi diet induced ↑ relative proportion of Faecalibacterium, Bacteroides and Akkermansia and ↓ relative proportion of Lachnospiraceae: Ruminococcus. |

(Continues)
interventions, which resulted in reduced total bacterial abundance in three trials [60%] (29,35,36) and no impact on bacterial abundance in the remaining two trials [40%] (16,31). The only trial that evaluated bacterial abundance after a non-hypocaloric but low-fat intervention showed an increase in bacterial abundance despite a comparable amount of weight loss (18).

Another evaluated criterion was intra-individual microbial richness [alpha diversity], as reported in four trials. Of those trials, 2 [50%] found increased richness after the dietary intervention (28,34), while the other 2 [50%] showed no impact (32,33).

Taxonomic analyses were performed in all of the included trials, although the reported results varied with respect to the use of targeted versus untargeted techniques to assess the composition profiles. The analysis of phylum composition was performed in eight trials, of which five observed no impact (15,27,30,32,33), two showed an increase in the relative abundance of Bacteroidetes along with a decrease in Firmicutes (16,18) and one trial reported the opposite effects in those phyla (31).

A species assessment was performed in 10 trials. Among those, six trials used similar interventions [hypocaloric, low carbohydrate and high protein], and all showed a reduction in Roseburia spp., Eubacterium rectale and other species belonging to the Clostridium Cluster XIVa as well as a reduction in Firmicutes sp. relative abundance (15,30–32,34,35). By contrast, the only trial using a non-hypocaloric but low-fat intervention found an increase in Clostridium Cluster IV, Bifidobacterium sp., Akkermansia muciniphila and Faecalibacterium prausnitzii (18). Changes in Lactobacillus sp., A. muciniphila and F. prausnitzii were not consistent among the studies, although we observed an increasing trend in the relative abundances of those species (18,28,30,31,33).

Among the included trials, three showed the importance of the intrapersonal microbiota composition and its consistency, despite the implementation of dietary interventions (16,35,36). In addition, a high bacterial gene count and a higher abundance of A. muciniphila correlated with better metabolic parameters, while the Lactobacillus/Leuconostoc/Pediococcus group abundance was related to a poorer profile of metabolic markers and weight regain (17,34,37). Furthermore, another trial suggested that the individual gut microbiota composition was a predictor of successful weight loss after very-low-calorie interventions, with higher frequencies of A. muciniphila and Dialister along with the abundance of Gordonibacter, Alistipes and Symbiobacterium being correlated with successful weight-loss maintenance (33).

As expected, carbohydrate restriction generally improved the metabolic parameters, including a reduction in the fasting blood glucose [FBG] (28,29,32–35), insulin resistance index [HOMA-IR] (29,33,34), blood lipids
Table 2 Characteristics of studies involving surgical interventions

| Study Identification | Intervention | Follow-up | Population | Outcomes |
|----------------------|--------------|-----------|------------|----------|
| Zhang et al., 2009   | RYGB         | Interval surgery evaluation >6 m | [3 each: eutrophic, obese, post-op] | Sex: 66% female, BMI: 48.3 ± 7.7 (obese) | Post-op (compared with eutrophic or obese): ↑Gammaproteobacteria and ↓Clostridium IV, ↑Enterobacteriaceae and Fusobacteriaceae. |
| Furet et al., 2010   | RYGB         | 24 weeks | [30 post-op and 13 lean] | Sex: 90% female, BMI: 47.6 ± 1.5 | Relative abundances: ↑F. prausnitzii, ↓Lactobacillus and Bifidobacterium, ↓FB ratio. |
| Kong et al., 2013    | RT           | Interval surgery evaluation: ±7 m | | Sex: 100% female, BMI: 47.6 ± 1.5 | Microbial richness estimated by Chao [58 new genera], ↑Firmicutes Blautia, Lactobacillus and Dorea, ↓Bacteroidetes, Alistipes and Proteobacteria E. coli. |
| Patil et al., 2012   | RT           | Interval surgery evaluation: ±7 m | [5 each: lean, eutrophic, obese, post-op] | Sex: 40% female, BMI: 15.0–53.0 | Post-op: No changes in microbial abundance and diversity, ↓Bacteroides and Archaea. |
| Graessler et al., 2013 | RYGB        | 12 weeks | | Sex: 50% female, BMI: 41.0–52.0 | Phylum: ↑Proteobacteria, ↓Firmicutes and Bacteroidetes; ↓FB ratio; ↓Alpha diversity; ↓Faecal pH. |
| Damms-Machado et al., 2015 | RT        | 24 weeks | [5 post-LSG versus 5 very-low-calorie diet] | Sex: 100% female, BMI: 45.8 ± 0.9 | Post-LSG: ↑Bacteroidetes, ↓Firmicutes [↓Clostridium clusters IV and XIaV], ↑Faecalibacterium, Dorea, Coprococcus and butyrate producers [E. rectale, Ruminococcus and Lachnospiraceae] and ↑FB ratio. |
| Tremaroli et al., 2015 | RYGB versus LSG | Interval surgery evaluation: 9.4 years | [7 post-RYGB, 7 post-VBG, 7 obese controls] | Sex: 100% female, BMI: 42.1 ± 4.2 | Significant differences in microbiota composition for RYGB versus OBS samples, but not for VBG versus OBS or RYGB versus VBG. |
| Patrone et al., 2016  | BIB          | 24 weeks | | Sex: 81.8% female, BMI: 47.4 ± 7.4 | ↑Alpha diversity; ↓Lactococcus and Clostridiales; ↑Enterobacter and Lactobacillus; ↓Faecal pH. |
| Palleja et al., 2016  | RYGB         | 52 weeks | | Sex: 61.5% female, BMI: >35.0 | Tendency to thinness, especially in the first 3 months; changes on beta diversity; ↑Proteobacteria and Fusobacteria; Changes in 19 species, including ↑Escherichia coli, Kebsiella pneumoniae, 10 species from Streptococcus, 4 from Veillonella, 2 from Alistipes, Bifidobacterium dentium, Enterococcus faecalis, F. nucleatum and Akkermansia muciniphila; besides ↓in F. prausnitzii. |
| Murphy et al., 2016   | RYGB and LSG | 52 weeks | | Sex: 42% female, BMI: 38.4 ± 5.2 | Greater relative abundance of Actinobacteria at baseline and increase in Roseburia after surgery correlated with T2DM remission. |

(Continues)
and inflammatory markers (28,32–34). Several correlations between bacterial taxa and metabolic parameters were found as follows. *A. muciniphila* was negatively correlated with FBG and triglycerides (17) and with metabolic syndrome in general (33); *Bifidobacterium* correlated with plasma insulin (36) and *F. prausnitzii* was inversely correlated with inflammatory markers (32). Furthermore, using a computational tool, Shoaie et al. (37) correlated a lower bacterial gene count with the production of several amino acids and metabolic diseases, and these authors showed that dietary intervention might reduce those products and therefore improve insulin sensitivity, reducing the cardiometabolic risk. Considering these trials, we could not relate the amount of weight loss to specific changes in the gut microbial composition.

*Surgical interventions (Table 2 – Extended version available [see Table S4]):*

Eleven papers reported the impact of surgical interventions for weight loss on the gut microbiota over 10 trials; eight of these were quasi-experimental studies (38–45), two were cross-sectional studies comparing the gut microbiota of post-bariatric patients and controls (46,47) and one was an RCT (48). The chosen surgical interventions varied; five studies involved Roux-en-Y gastric bypasses [RYGB] (38–40,43,46), two used biliary-intestinal bypasses [BIB] (42,45) and in two other studies, the technique was primarily restrictive (laparoscopic sleeve gastrectomy [LSG] or gastric banding [GB]) (41,47). The remaining two studies compared RYGB to LSG (44,48). The number of patients included in each study varied between 6 and 56 [average: 21, SD: 15].

The techniques used to assess the gut microbiota in the included studies were as follows: five studies [45%] used metagenomics [shotgun sequencing] (40,41,43,44,48), four studies [36%] used 16S rRNA gene metabarcoding [a group-specific qPCR was also performed in two of them] (39,42,46,47), one study [9%] used DGGE (45) and one study [9%] used only group-specific qPCR (38).

The differences between obese and normal-weight individuals were assessed in five studies. Federico et al. (45) observed differences in the microbial community fingerprints between normal-weight and obese individuals using DGGE. The remaining four trials involved taxonomic analysis. In 75% of cases, there was a higher level of the Bacteroidetes phylum [*Prevotella* sp.] (38,46,47), and 50% also reported a higher level of Archaea in obese patients (38,46,47). In contrast, Patrone et al. (42) found a reduced Bacteroidetes rate in obese patients relative to that in normal-weight patients, with a remarkably lower count for that phylum percentage. A reduced *A. muciniphila* abundance and a higher SCFA production were also reported in obese patients (46,47).

We included five studies using RYGB surgery (38–40,43,46), covering four different trials. One study reported an...
| Study Identification | Study Intervention | Follow-up | n | Description | Microbiota | Outcomes | Anthropometry |
|----------------------|--------------------|-----------|---|-------------|------------|----------|--------------|
| Christensen et al., 2013 | Prebiotic: Hypocaloric diet + whole-grain wheat [RGW] + refined wheat [RW] | 12 weeks | 72 | Sex: 100% female BMI: 27.0–37.0 | WW promoted 1. Bifidobacterium and RW promoted 2. Bacteroides. No further impact on microbiota. | Both RW and WG showed [BW] vs [ns]. The BF increased greater in the WW group [−3%] than in the RW group [−2.1%]. | No impact on BW or WC, [0.7%] vs [ns] |
| Dewulf et al., 2013 | Prebiotic: Supplementation with inulin-type fructans [ITF] | 12 weeks | 44 | Sex: 100% female BMI: 36.1 ± 4.1 [ITF], 35.6 ± 4.3 [placebo] | ITF-induced changes in phylum [↑Firmicutes and Actinobacteria, ↓Bacteroides], genus levels [↑Clostridium cluster IV and XV, Bifidobacterium, Lactobacillus] and ↓1.4% BMI, ↓Diversity vs placebo. Phylum: no impact on phylum diversity [NS]. | Probiotic group showed greater ↓1 in BW [±1.1%], correlated with body water content. No impact on WC or BF. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Sharafedtinov et al., 2013 | Probiotic: Hypocaloric diet + L. plantarum cheese versus placebo cheese | 3 weeks | 40 | Sex: 67% female | Total bacterial: no impact on probiotic group, but in controls. Lactobacillus count: no impact on probiotic group, but tended to ↓ in controls. | Probiotic group showed greater ↓1 in BW [±1.1%], correlated with body water content. No impact on WC or BF. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Omar et al., 2013 | Probiotic: 42-day interventions + 6-week washout (control, L. fermentum[LF], L. amylovorus [LAL]) | 25 weeks | 28 | Sex: 64% female BMI: 31.6 ± 0.7 | LA and LF: ↑Lactobacillus compared with control. No impact on Bacteroides, Bifidobacterium. Clostridium Cluster IV, Roseburia or Enterobacter compared with control. LA inhibited Clostridium Cluster IV. | Overall, no impact on WJBF. Treatment versus sex interaction: 40% greater ↓ in BW and 55% greater ↓ in JBF in LPR-treated women. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Sanchez et al., 2014 | Prebiotic: 2-week washout + 12-week energy restriction + 12 weeks no energy restriction, both with L. rhamnosus [LPR] versus placebo | 26 weeks | 125 | Sex: 61% female BMI: 33.8 ± 3.3 [LPR], 33.3 ± 3.2 [placebo] | In general, no impact on gut microbiota diversity or composition [phylum, class, order, family or genus]. A treatment versus sex interaction with ↓Lachnospiraceae, mainly Roseburia 1 [LPR vs placebo]. | Overall, no impact on WJBF. Treatment versus sex interaction: 40% greater ↓ in BW and 55% greater ↓ in JBF in LPR-treated women. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Song et al., 2014 | Prebiotic: Supplementation with Panax ginseng extracts | 8 weeks | 10 | Sex: 100% female BMI: 28.3 ± 2.0 | ↑Diversity in 5 and ↓ in 3 patients. No impact on phylum distribution. Genus dominance changed from Blautia, Bifidobacterium and Anaerostipes to Bifidobacterium, Blautia, Faecalibacterium after intake. Effective weight-loss group had richness and predominance of Firmicutes, Tenericutes and Bacteroidetes. | [1.4% BMI, ↓WC [ns], ↑1.5% JBF] LPR-treated women. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Kim et al., 2014 | Prebiotic: Supplementation with Ephedra extracts | 8 weeks | 7 | Sex: 100% female BMI: 30.1 ± 3.3 | Gut microbial changes in phylum/genus composition were dependent on unique basal microbiota composition. Diversity in 4 and ↓ in 3 patients. | [2.6% BMI, no impact on WC, ↑2.7% JBF] All groups had changes in body compositions parameters, but no difference probiotic versus placebo. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Lee et al., 2014 | Symbiotic: Botfasushiroman [BTS] + probiotic versus BTS + placebo | 8 weeks | 50 | Sex: 100% female BMI: 28.3 ± 1.3 | Probiotic: ↑Bifidobacterium [B. breve, B. lactis] and ↑Lactobacillus [L. rhamnosus] compared with placebo. No impact on total bacterial abundance. | Both groups had changes in body compositions parameters, but no difference probiotic versus placebo. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Remely et al., 2015 | Probiotic: 7-day fasting + laxatives, followed by 6-week probiotics [7 strains of Bifidobacterium sp. and Lactobacillus sp.] | 7 weeks | 13 | Sex: NA BMI: 28.1 ± 3.5 | No impact on bacterial abundance. ↑1Bacterial diversity. Phylum: no impact on Bacteroidetes [Bacteroides or Prevotella] or Firmicutes or F:B ratio. Class: no impact on Clostridiales IV or XIVa. Species: ↑1. F. prausnitzii [main butyrate producer], ↑1. Bifidobacteria sp., ↑1. A. muciniphila. | Both groups had changes in body compositions parameters, but no difference probiotic versus placebo. | No impact on BW or WC: greater ↓1 in BF both with LF [3%] and LA [4%] compared with control [1%]. |
| Han et al., 2015a | Prebiotic: Supplementation of Rhizomma glutinoso | 8 weeks | 12 | Sex: 100% female BMI: 27.8 ± 3.9 | Phylum: ↑Actinobacteria, ↓Firmicutes, ↓Bacteroidetes; Genus: dominance changed from Blautia to Bifidobacterium and ↓Eubacterium. | [BW] vs [ns], ↑2.6% BMI, no impact on JBF | No impact on BW compared with placebo, but promoted greater ↓ in WC and JBF. | No impact on BW compared with placebo, but promoted greater ↓ in WC and JBF. |
| Song et al., 2015 | Prebiotic: Supplementation with Schisandra chinensis fruit [SCF] versus placebo | 12 weeks | 28 | Sex: 100% female BMI: 29.9 ± 4.2 | SCF: No impact on phylum composition [SCF and placebo showed ↑Firmicutes and ↓Bacteroidetes], but major impact on genus composition [↑A. muciniphila, Roseburia, Bacteroides, Prevotella, Bifidobacterium and ↓Ruminococcus]. | No impact on BW compared with placebo, but promoted greater ↓ in WC and JBF. | No impact on BW compared with placebo, but promoted greater ↓ in WC and JBF. |

(Continues)
| Study                | Intervention                                                                 | Population | Outcomes                                                                 | Anthropometry                                                                 |
|---------------------|------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Han et al., 2015b   | Prebiotic: Supplementation with fresh kimchi versus fermented kimchi         | 8 weeks    | 23 Sex: 100% female BMI: 23 ± 2.3 (fresh), 27.8 ± 2.2 (fermented)         | Both groups: ↓F/B ratio and ↑Proteobacteria and Actinobacteria. Fermented kimchi: ↑Bacteroides, Prevotella and Bifidobacterium, ↓Blautia |
| Karl et al., 2015   | Prebiotic: 9 weeks hypocaloric diet with whole grains, herbal medicines and prebiotic [guargun, pectin, konjac flour] + 14 weeks maintenance | 23 weeks   | 77 Sex: 63% female BMI: 32.3 ± 2.9                                      | ↓Alpha diversity. Inter-individual variability > intra-individual variation. Phylum: ↑Actinobacter and ↓Proteobacter; no impact on Firmicutes, Bacteroidetes or F/B ratio. Family: ↑Bifidobacteriaceae and ↓Enterobacteriaceae and Desulfovibrionaceae. |
| Uphadyaya et al., 2016 | Prebiotic: 12 weeks interventions (resistant starch type 4 [RST4] versus placebo) with 2-week wash-out periods | 26 weeks   | 20 Sex: 60% female BMI: 32.8                                           | ↓RST4 compared with placebo: No impact on bacterial diversity; modifications in 71 OTUs, including ↑Ruminococcus, Blautia, Bacteroides, Oscillospira, Parabacteroides. Overall, tended to ↑Bacteroidetes and reduce F/B ratio. ↓-Es and post-RST4: ↑Clostridium Cluster XIVa [but not Cluster IV]; ↑Bifidobacterium and Parabacteroides. No impact on Ruminococcus, F. prausnitzii and Dorea. |
| Takahashi et al., 2016 | Probiotic: 12-week supplementation with Bifidobacterium animalis ssp. [BA] versus placebo | 12 weeks   | 160 Sex: 36.4% female BMI: 26.8 ± 1.5                                  | BA group showed total bifidobacteria counts and B. lactis No impact on B. bifidum, B. breve, B. longum, B. adolescentis, B. anguilatum, B. catenulatum, B. dentium and B. infantis. No differences between BA and placebo on BMI changes. |

Symbols

*BF analysis using dual energy X-ray absorptiometry [DEXA].
*BF analysis using bioelectrical impedance analysis [BIA].

Units: Age [in years] shown in range or mean ± standard deviation, BMI [kg/m²] shown in range or mean values ± standard deviation and anthropometric parameters are shown in percentage changes. BA, Bifidobacterium animalis ssp.; BIA, bioelectrical impedance analysis; BTS, Bofutsushoan; BF, body fat; BMI, body mass index; BW, body weight; F/B ratio, Firmicutes to Bacteroidetes ratio; ITF, inulin-type fructans; LA, Lactobacillus amylovorus; LF, Lactobacillus fermentum; LPR, Lactobacillus plantarum rhamnosus; MetS, metabolic syndrome; NA, not available, ns, not significant; NSP diet, non-starch polysaccharides; RGW, refined grain wheat; SCF, Schisandra chinensis fruit; SCFA, short-chain fatty acids; WC, waist circumference; WGW, whole grain wheat.
increase in bacterial richness (43). Upon comparing the composition of gut microbiota pre- and post-RYGB procedure, a data analysis of those four trials showed no difference in the phylum level, although a decreasing Firmicutes trend and an increase in Proteobacteria were observed at the post-operative stage. Furthermore, all four trials showed an increase in Escherichia coli [phylum Proteobacteria], and 75% reported a decrease in Lactobacillus sp. [phylum Firmicutes] (38–40). Moreover, a decrease in the Blautia, Dorea [phylum Firmicutes] and Bifidobacterium [phylum Actinobacteria] genera was reported (39). The abundance of F. prausnitzii, a member of the Clostridiaceae family [phylum Firmicutes], showed inconsistent results. The Firmicutes to Bacteroidetes ratio was reduced in 75% of the included studies.

Laparoscopic sleeve gastrectomy, which is primarily a restrictive surgical technique, was assessed in two studies (41,47). Damms-Machado et al. (41) reported that LSG promoted more profound changes in the gut microbiota composition than a very-low-calorie diet, despite producing similar weight loss. These changes included a decrease in Firmicutes along with an increase in Bacteroidetes and were comparable to the RYGB result. Specifically, Clostridium Clusters IV and XIV, Dorea, Faecalibacterium and butyrate producers [Eubacterium rectale, Ruminococcus and genera from the Lachnospiraceae family] were decreased. The Firmicutes to Bacteroidetes ratio was again reduced. A cross-sectional study including post-LSG patients showed no impact on the bacterial diversity and decreased Bacteroides and Archaea (47).

One study using the BIB technique reported a reduction in the bacterial richness, and, along with the results from the RYGB technique, there was an increase in Proteobacteria [family Enterobacteriaceae]. As shown for restrictive techniques, the abundance of butyrate producers [order Clostridiales, including the Faecalibacterium, Ruminococcus, Clostridium and Eubacterium genera] was reduced (42). The impact of BIB was also evaluated by Federico et al. (45), who showed different microbial community fingerprints before and after surgery. Using DGGE, they showed that the abundant bands found for the obese population were absent after the intervention, along with an increase in the band that corresponded to Lactobacillus sp.

Two studies compared different surgical interventions for weight loss (44,48). While Tremaroli et al. (48) did not observe any differences between the microbial profiles after RYGB and vertical banded gastroplasty [VBG], Murphy et al. (44) observed an increase in the bacterial diversity and a decrease in the relative abundance of Bacteroidetes after RYGB but no impact on the diversity and an increased relative abundance of Bacteroidetes after LSG.

Considering the amount of weight loss, RYGB [five studies] exerted a major impact on weight reduction, showing 21–27% losses, while RT [three studies] resulted in body weight reductions of 20–24%, and BIB [two studies] led to body weight reductions of 16–18%.

Improvements in metabolic markers, including a reduction in FBG and blood lipids and a reduction in blood pressure [BP], were reported regardless of the chosen technique, although correlations with bacterial taxa were conflicting. Graessler et al. (40) found a positive correlation between F. prausnitzii and FBG, unlike Furet et al. (38). Another study also found a negative correlation between FBG and Lactobacillus (42). Inflammatory markers were positively correlated with Propionibacterium (44) and negatively correlated with F. prausnitzii (38).

-Microbiota interventions (Table 3 – Extended version available [see Table S5]):

Three types of microbiota-driven therapies for weight loss were identified among the included studies: probiotics, symbiotics and prebiotics. Probiotics are live microorganisms that can reach the intestines in an active state and promote positive health effects, while prebiotics are selectively fermented ingredients that allow specific changes in the composition and/or activity of gut microbiota, thereby conferring benefits. The synergistic combination of pre- and probiotics is known as symbiotics (49).

From the 13 studies that included direct interventions in the gut microbiota, five involved probiotics, one used symbiotics and nine included prebiotics. Considering the study design, six were single-group assessments (50–55) and nine were RCTs [seven with parallel assignments and two with a cross-over design] (23,56–63). The number of patients included in each trial varied between 7 and 160 [average: 47, SD: 44]. The length of the intervention varied between 3 and 26 weeks [average: 13 weeks, SD: 8].

The techniques used here to assess the gut microbiota in the included studies were as follows: seven studies [47%] involved 16S rRNA gene metabarcoding [one also included a qPCR analysis of specific taxa] (23,51,52,54,55,61,62), five studies [33%] used only qPCR (50,57–59,63) and three studies [20%] combined qPCR with HITChip analysis or DGGE (53,56,60).

The impact of six types of probiotics on weight loss was assessed in five studies (23,53,57,58,63). In four studies performed to test 5 [80%] different probiotic strains [Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus amylovorus, Bifidobacterium animalis or a mix of strains], there was no impact on body weight. Of those, the study using L. rhamnosus reported a pronounced treatment–sex interaction, with a reduction in the Lachnospiraceae family along with a body weight and fat percentage reduction after a probiotic intervention in women (23). Body fat was also decreased after L. fermentum and L. amylovorus intake (58). One study [25%] on Lactobacillus plantarum associated probiotic intake with weight loss (57). Probiotic intake was also correlated with changes in the relative abundance of
Clostridium Cluster IV, Bifidobacterium and A. munitiphila, with differences between trials. While L. amylovorus inhibited Clostridium Cluster IV, the mix of different strains did not exert any impact on the cluster. Bifidobacterium was increased after the intake of either the mix of strains or the intake of B. animalis, although this genus showed no changes in relative abundance after L. fermentum or L. amylovorus intake.

One study used a symbiotic intervention (a combination of seven probiotic strains and herbal medicine [Botufusushosan]), resulting in increased Bifidobacterium and Lactobacillus abundance, but there was no impact on body weight (59).

The use of prebiotics was assessed in nine trials (50–52,54–56,60–62). The tested prebiotics varied and included the following: inulin-type fructans [ITF] (56), Rehmannia glutinosa (54), Schisandra chinensis fruit [SCF] (60), kimchi (61), whole grains (50), Ephedra (52), Panax (51), resistant starch type 4 [RST4] (62) or a combination [guar gum, pectin and konjac flour] (55). The impact of the interventions on the gut microbiota phylum composition varied, and 71% of the included studies showed an increase in the Actinobacteria phylum (50,54–56,59,61). Further changes included an increasing tendency for important bacterial groups such as Clostridium Clusters IV and XIVα, Lactobacillus and F. prausnitzii [phylum Firmicutes], A. munitiphila [phylum Verrucomicrobia] and Bifidobacterium [phylum Actinobacteria], with decreases in Bacteroides [phylum Bacteroidetes] and Enterobacter [phylum Proteobacteria]. Additionally, two trials showed that the impacts of the compounds as prebiotics were dependent on the individual gut microbiota composition, and the authors suggested that the different dietary patterns and preferred foods, digestive times [transit time and digestive secretions], and age, among other factors, could determine the baseline richness and taxonomic microbial composition of the gut microbiota and their changes following prebiotic intervention (51,52).

Over half of these studies [55%] reported no impact on body weight (50,54,56,60,62), while the remaining trials showed weight loss (51,52,55,61). In addition, 75% of studies reported body fat reductions (50–52,60–62).

In general, the manipulation of gut microbiota with the use of pro-, pre- or symbiotics had no impact on BP or metabolic markers such as FBG and blood lipids. However, some compounds tended to improve the blood lipid profile (54,55,57,60) and to reduce the levels of inflammatory markers (55,56). In addition, some correlations between bacterial taxa and metabolic markers were found. For instance, the FBG was positively correlated with Roseburia (52) and negatively correlated with Blautia (54), Ruminococcus (60), Enterobacter (52) and Clostridium Cluster IV (56). In addition, the total cholesterol was negatively correlated with Parabacteroides and Oscillospira, and the Low-density-lipoprotein [LDL] cholesterol was correlated with Methanobrevibacter and Ruminococcus (62).

Quality assessment
Among the included studies, 18 involved an evaluation of the RoB through an RoB [RCT] and 25 included RoBANs [NRCT] [See Table S6: Quality Assessment]. Using the RoB evaluation, 77% presented adequate sequence generation, 61% reported allocation concealment, 55% had the authors blinded to individual data, 100% involved a blinded assessment of outcomes, 50% reported losses in the follow-up and exclusions, 88% reported suggested information and 77% were judged free of other sources of bias. Considering the RoBANs, 52% presented an adequate patient selection, 48% were judged to be free of confounding variables, 84% had adequate exposure measurements, 100% had blinded outcomes, 48% reported drop-outs and 56% reported the suggested information.

Discussion
The growing interest in gut microbiota studies in the obesity field is motivated by the possibility that gut microbiota manipulation may help in achieving sustained weight loss. Our review shows that any type of weight-loss intervention [dietary, surgical or direct manipulation of gut microbiota] impacts the gut microbiota composition, although this impact is not always correlated with the amount of weight loss. More importantly, it appears that the baseline composition of the gut microbiota influences responses to weight-loss interventions. This is the first systematic review to assess different approaches to obesity and their relations to the gut microbiota.

The gut microbial composition is unique to each person and is strongly influenced by environmental factors, such as genetics, the delivery route, infant feeding patterns, sanitary conditions and antibiotic usage (64). Marked changes in the microbiota composition occur in early infancy, after which point it becomes relatively stable (65). Long-term dietary patterns have a powerful influence on the gut microbiota composition (66), and they are associated with the three gut microbiota profile variants [clusters], which are known as ‘enterotypes’ (67). The enterotypes are divided according to the predominance of Bacteroides [which is associated with high-protein and animal fat diets], Prevotella [which is associated with carbohydrate-rich diets] or Ruminococcus, and these enterotypes might correlate with individual health status. However, lifestyle modifications, dietary changes and supplements rapidly and broadly impact microbiota dynamics, which might occur on a day-to-day timescale (68).
The first challenge in summarizing the results of this review was that several different molecular biology techniques [DGGE, FISH, qPCR, 16S rRNA metabarcoding and shotgun sequencing] have been used to assess the gut microbial composition, which results in distinct ways of presenting microbiota changes. These assessments include differences at the taxonomic level [phylum, genus and species] and other characterizations of microbiota, such as richness [alpha diversity] and inter-individual variation [beta diversity]. Even when the same data type [shotgun sequencing or 16S rRNA metabarcoding] is present, differences in clustering methodology, distance metrics, operational taxonomic units (OTU)-picking approaches and the sequencing depth or 16S rRNA region represent possible sources of differing results (69). In addition, the methodology for faecal specimen collection and storage lack uniformity among the studies included herein, which may alter the reported microbial composition (70). Considering those differences and the small number of patients tested using similar methods to assess the same class of organisms, this was the first obstacle to conducting a meta-analysis.

Another challenge was that several intervention types and lengths were used, and there was a wide range of study designs. Most of our included studies were not optimal for assessing the relation between interventions on the gut microbiota and weight, as only 18 [41%] were RCTs.

Furthermore, the assessed RoB for the included studies generally showed poor to moderate quality due to the potential sources of bias. These biases included the use of small samples [58% of the studies included fewer than 30 patients], broad criteria for patient inclusion [diverse BMIs, genders and ages], a lack of controls, a poor description of population characteristics and consideration of potential confounding issues.

Another possible confounder for microbiota composition results is the presence of comorbidities, which were not always described in the included studies. Historically, obesity was associated with an increased relative abundance of Firmicutes and decreased Bacteroidetes (16,18,38,54); however, this association was not supported in further studies (15,33,41,47). One of the possible explanations for those divergent results is the presence of comorbidities. Specifically, the presence of type 2 diabetes has been associated with an increased Firmicutes/Bacteroidetes ratio (31).

Despite the aforementioned issues, this review highlights the following observations. First, when considering dietary interventions, restrictive diets seem to promote a reduction in gut microbiota diversity, which is correlated with macronutrient deficiency rather than weight loss. For instance, carbohydrate restriction might lead to changes in the activity and abundance of several bacterial groups (29). Dietary fat intake impacts the gut microbial composition, intestinal permeability and metabolic endotoxaemia (71). In addition, high-protein diets also exert impacts on the gut microbiota by reducing microbial diversity and changing the taxon profiles (72). In addition to these phenomena, the dietary interventions in this review led to a reduction in certain bacterial groups, such as the abundance of the butyrate-producing Firmicutes [Clostridium Clusters IV and XIVa], Lactobacillus sp. and Bifidobacterium sp. These results indicate a reduction in complex carbohydrate intake and suggest that these bacteria function as prebiotics (73).

The included studies with dietary interventions for weight loss also indicate that the inter-individual differences in the microbiota composition at the baseline are important (30,36,74) and might be a useful tool for predicting weight-loss responses and the best individual therapies in the future (33). Further studies also show that the baseline microbiota composition can predict responsiveness to weight-loss diets, including metabolic improvement (75), besides influencing responses to prebiotic interventions (76,77). Microbial richness plays a role in individual responses to dietary interventions, and low microbial gene counts indicate a poor response to the intervention. However, weight-loss diets were able to increase the microbial gene richness in some studies, suggesting an advance from risk detection to risk alleviation (34).

Furthermore, the higher relative abundance of A. muciniphila, a mucus-degrading bacterium, seems to play a role in the response to dietary interventions and weight trajectory success (17,33,35,36); this same bacterium has been associated with intestinal integrity, glucose homeostasis and cardiometabolic health (17). Another microbe with a promising role in maintaining health is F. prausnitzii, a butyrate producer that is related to the lean phenotype and is capable of improving gut barrier function (78). These observations highlight the possible benefit of personalized approaches to weight management that account for the baseline composition of individual microbiota.

Data collected from surgical interventions suggest that gut microbiota changes occur due to several factors, related to the technique used. Laparoscopic sleeve gastrectomy, a primary restrictive procedure, induces the smallest impact on the gut microbiota, which is related to bacterial adaptation to caloric restriction; this process leads to similar changes as those observed with dietary restriction and other surgical techniques (41). This reduction in the Firmicutes phylum and therefore the fermentation activity may result in reduced energy harvest and SCFA production, such as acetate and propionate, which are substrates for gluconeogenesis and lipogenesis (41). Roux-en-Y gastric bypass also induces a similar decrease in the presence of the Firmicutes phylum, yet it promotes wider microbial adaptation, possibly because the anatomic changes provoke the exposure of the remnant stomach to higher gastric acid
levels and reduce the absorptive intestinal surface (41). In addition, the ingestion transit time is accelerated, and the increased intestinal pH modifies the oxidoreduction potential in the gut, likely affecting aerobes and facultative aerobic microorganisms, such as Proteobacteria. The increase in Proteobacteria in the gut after RYGB might also be related to reduced bacterial translocation in the blood along with improved insulin resistance and systemic inflammation, as these species account for the majority of blood bacterial DNA (39). An increase in E. coli [phyllum Proteobacteria] could contribute to energy harvest, as animal data show that E. coli might help the host to survive under starvation situations (39). Although those changes improve metabolic markers, there are concerns about the risk of colon inflammation and colorectal cancer [CRC], which are especially attributed to increases in Enterobacter cancerogenus, Shigella boydii and Salmonella enterica and to a reduction in butyrate-producing Firmicutes (40).

The included studies involving probiotic interventions were highly diverse in duration, strain and concentration. While L. plantarum promoted body weight reduction, L. fermentum and L. amylovorus had no impact on body weight but reduced the body fat content. Furthermore, L. rhamnosus generally had no impact on anthropometric markers, yet it was able to reduce body weight and body fat in women. Additional studies that did not fulfil the inclusion criteria for this systematic review also reported associations between certain strains and weight changes. In 2011, a systematic review on this topic reported the associations of L. acidophilus, L. fermentum and L. inulgustei with weight gain and L. plantarum and L. gasseri with weight loss (79). Later, there was criticism about those conclusions because the weight gain observed for some species was seen in children and could therefore represent their physiological development and growth rather than indicate an increased risk for obesity development in adulthood (80). More recently, further systematic reviews including clinical trials with probiotic interventions for weight loss were performed, with divergent results. While one group concluded that probiotics had limited effects in terms of reducing body weight, another concluded that their intake could reduce body weight, especially if multiple strains are used (81,82).

The intake of prebiotics, or compounds that resist digestion in the small intestine and reach the colon to be fermented by gut microbes, as primarily represented by carbohydrates, was also evaluated. An analysis of the studies included in this systematic review shows that not only oligosaccharides can act as prebiotics, but that other compounds are also able to promote changes in the composition and function of gut microbiota, including the increase of bifidobacteria. Along with this bifidogenic effect, prebiotic intake facilitates a cross-feeding interaction that results in an increase in butyrate producers and butyrate synthesis, which contributes to gut barrier function, immunomodulation and anti-inflammatory properties, as this fatty acid is the preferred source of energy for colonocytes (83). Accompanying this information, this review suggests a possible benefit of prebiotic intake, which is primarily due to fat mass reduction and improved metabolic outcomes such as reduced glucose tolerance and lipid metabolism. Furthermore, a published meta-analysis found a reduction in the total plasma cholesterol, triglycerides and fasting insulin after pre- and symbiotic intake in the overweight or obese population (84). However, the potential benefit of this approach is likely to be dependent on the individual gut microbiota composition and long-term dietary pattern, specifically fibre intake (85).

The observed results after the manipulation of the gut microbiota in the included studies suggest a possible causal effect of the microbiota composition on weight management and metabolism. In line with these observations in humans, animal studies have shown that transplanting the intestinal microbiota of mice that were discordant for obesity and comorbidities impacted the weight gain, insulin resistance and development of non-alcoholic fatty liver disease in recipient mice (86,87). Furthermore, a human study showed that an infusion of intestinal microbiota from lean donors to metabolic syndrome patients promoted changes in the gut microbial composition and improved insulin sensitivity (88). However, in light of current knowledge, a conclusion about the causal versus consequential effects of the gut microbial composition and the exact species involvement in weight management in humans is not yet possible.

Despite the great reduction in morbidity and mortality usually associated with weight loss in obese populations, changes in the gut taxonomic profiles and microbial products might be detrimental to the colon. Some types of diets that are commonly used for weight loss (e.g. high-protein low-fibre diets) can contribute to the production of dietary components and metabolites that contribute to intestinal inflammation, reactive oxygen species [ROS] production and genotoxicity, increasing the risk of CRC (89). Reductions in butyrate producers and increased Proteobacteria are common after dietary products might be detrimental to the colon. Some types of diets that are commonly used for weight loss (e.g. high-protein low-fibre diets) can contribute to the production of dietary components and metabolites that contribute to intestinal inflammation, reactive oxygen species [ROS] production and genotoxicity, increasing the risk of CRC (89). Reductions in butyrate producers and increased Proteobacteria are common after dietary and surgical interventions for weight loss, and they are also associated with colon cancer (90). Microbiota-targeting therapy, such as the use of pre- or probiotics, has been suggested to combat CRC-associated dysbiosis (91).

In summary, the available results in humans suggest that any intervention type for weight-loss impacts the gut microbiota; however, the relationship between the gut microbial composition and weight management remains to be determined.
Limitations

This review provides a comprehensive update on this topic, although certain limitations should be acknowledged. The different protocols used to collect the faecal material along with the wide range of methodologies [targeted vs. untargeted] used to assess the gut microbiota resulted in different ways to present data about microbial abundance and composition [with different levels of assessment]. Furthermore, several study designs [RCTs, NRCTs, observational studies and quasi-experimental studies] were implemented, and these also represented a limiting factor in generalizations. In addition, the length of the intervention and observation periods and differences in the populations [age, gender, comorbidities and geographic location] might represent confounding factors. A meta-analysis of the results was not feasible or appropriate; therefore, generalizations should be made with caution.

Conclusions

This review systematically assessed studies of weight-loss interventions in obese and overweight patients. There were significant differences in the methodology, design, length of intervention and observation among the included studies, and their risks of bias were generally considered to be low to moderate. The gut microbial composition is unique to each person and is strongly influenced by several factors. This review shows that any type of intervention for weight loss [dietary, surgical or the use of pre-, pro- or symbiotics] impacts the gut microbiota composition, but this impact is not always correlated with the amount of weight loss. More importantly, it appears that the baseline composition of gut microbiota might influence individual responses to weight-loss interventions. Restrictive diets and bariatric surgery seem to reduce microbial abundance and promote changes in composition that might be detrimental to the colon in the long-term. The use of prebiotics might be able to restore a healthy gut microbiome in addition to reducing body fat. Further trials that include a larger number of patients are needed to draw conclusions about the role of specific bacterial taxa in human health and to evaluate the impact of specific probiotics on gut microbiota.

Declarations

All of the authors approved this manuscript before submission. All of the data used to prepare this manuscript are available.

Acknowledgements

We thank Rita Mattiello for her support.

Conflict of interest statement

The authors have no potential conflicts of interest, including specific financial interests or relationships and affiliations relevant to the subject matter or material disclosed in the manuscript. M.D. Seganfredo reports receiving personal fees [PhD Scholarship] from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES while conducting this study.

Funding

This study was supported by a grant from the Brazilian Federal Agency for Support and Evaluation of Graduate Education [CAPES].

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article. http://dx.doi.org/10.1111/obr.12541

Table S1. Search strategy.
Table S2. Molecular biology techniques.
Table S3. Extended version of characteristics of studies with dietary interventions.
Table S4. Extended version of characteristics of studies with surgical interventions.
Table S5. Extended version of characteristics of studies with microbiota interventions.
Table S6. Risk of bias assessment.

References

1. Organisation WH. Obesity and overweight: World Health Organisation; 2016 [updated January, 2015. Fact sheet N°311: Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.
2. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10: 97S–104S.
3. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 2010; 3: 283–295.
4. Morgen CS, Sorensen TL. Obesity: global trends in the prevalence of overweight and obesity. Nat Rev Endocrinol 2014; 10: 513–514.
5. McAllister EJ, Dhurandhar NV, Keith SW et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 2009; 49: 868–913.
6. Baothman OA, Zamzami MA, Taher I, Abubaker J, Abu-Farha M. The role of gut microbiota in the development of obesity and diabetes. Lipids Health Dis 2016; 15: 108.
7. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279–288.
8. Corfe BM, Harden CJ, Bull M, Garaioa I. The multifactorial interplay of diet, the microbiome and appetite control: current knowledge and future challenges. Proc Nutr Soc 2015; 74: 233–244.
9. Bauer PV, Hamr SC, Duca FA. Regulation of energy balance by a gut–brain axis and involvement of the gut microbiota. Cell Mol Life Sci 2016; 73: 737–755.

10. Kallus SJ, Brandt LJ. The intestinal microbiota and obesity. J Clin Gastroenterol 2012; 46: 16–24.

11. Bäckhed F, Manchester JK, Semenovich CF, Gordon JL. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007; 104: 979–984.

12. Bäckhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718–15723.

13. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JL. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027–1031.

14. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JL. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 11070–11075.

15. Duncan SH, Lobley GE, Holtrop G et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes 2008; 32: 1720–1724.

16. Ley RE, Turnbaugh PJ, Klein S, Gordon JL. Microbial ecology: environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2012; 109: 9348–9353.

17. Yao MC, Everard A, Aron-Wisnewsky J et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 2016; 65: 426–436.

18. Remely M, Tesar I, Hippe B, Gnauer S, Rust P, Haslberger AG. Gut microbiota composition correlates with changes in body fat content due to weight loss. Benefic Microbes 2015; 6: 431–439.

19. Westerveld D, Yang D. Through thick and thin: identifying barriers to bariatric surgery, weight loss maintenance, and tailoring obesity treatment for the future. Surg Res Pract 2016; 2016: 8616581.

20. Li Z, Maglione M, Tu W et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532–546.

21. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 2014; 149: 275–287.

22. Lauti M, Kularatna M, Hill AG, McCormick AD. Weight regain following sleeve gastrectomy—a systematic review. Obes Surg 2016; 26: 1326–1334.

23. Sanchez M, Dorimont C, Drapeau V et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br J Nutr 2014; 111: 1507–1519.

24. McHugh ML. Interarrat reliability: the kappa statistic. Biochem Med (Zagreb) 2012; 22: 276–282.

25. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

26. Kim SY, Park JE, Lee YJ et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013; 66: 408–414.

27. Haro C, Montes-Borrego M, Rangel-Zúñiga OA et al. Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J Clin Endocrinol Metab 2016; 101: 233–242.

28. Candela M, Biagi E, Soverini M et al. Modulation of gut microbiota dysbiosis in type 2 diabetic patients by probiotic Ma-Pi 2 diet. Br J Nutr 2016; 116: 80–93.

29. Duncan SH, Belenguer A, Hol trop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 2007; 73: 1073–1078.

30. Walker AW, Ince J, Duncan SH et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011; 5: 220–230.

31. Remely M, Hippe B, Zanner J, Aumueller E, Brath H, Haslberger AG. Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss. Endocr Metab Immune Disord Drug Targets 2016; 16: 99–106.

32. Pataky Z, Genton L, Spahr L et al. Impact of hypocaloric hyperproteic diet on gut microbiota in overweight or obese patients with nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2016; 61: 2721–2731.

33. Louis S, Tappu RM, Damms-Machado A, Huson DH, Bischoff SC. Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenomic shotgun sequencing. PLoS One 2016; 11: e0149564.

34. Cotillard A, Kennedy SP, Gotzsche PC et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. JAMA Surg 2016; 151: 1519–1520.

35. Simoes CD, Maukonen J, Scott KP, Virtanen KA, Pietilainen KH, Saarela M. Impact of a very low-energy diet on the fecal microbiota of obese individuals. Eur J Nutr 2014; 53: 1421–1429.

36. Salonen A, Lahit L, Saloravji J et al. Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men. ISME J 2014; 8: 2218–2230.

37. Shoaei S, Ghaffari P, Kovatcheva-Datchary P et al. Quantifying diet-induced metabolic changes of the human gut microbiome. Cell Metab 2015; 22: 320–331.

38. Furet JP, Kong LC, Tap J et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59: 3049–3057.

39. Kong LC, Tap J, Aron-Wisnewsky J et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 2013; 98: 16–24.

40. Grasberger J, Qin Y, Zhong H et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics 2013; 13: 514–522.

41. Damms-Machado A, Mitra S, Schollenberger AE et al. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. Biomed Res Int 2015; 2015: 806248.

42. Patrone V, Vajena E, Minuti A et al. Postoperative changes in fecal bacterial communities and fermentation products in obese patients undergoing bilio-intestinal bypass. Front Microbiol 2016; 7: 200.

43. Palleja A, Kashani A, Allin KH et al. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med 2016; 8: 67.

44. Murphy R, Tsai P, Jillig M, Liu A, Plank L, Booth M. Differential changes in gut microbiota after gastric bypass and sleeve gastrectomy bariatric surgery vary according to diabetes remission. Obes Surg 2016.

45. Federico A, Dallio M, Tolone S et al. Gastrointestinal hormones, intestinal microbiota and metabolic homeostasis in obese patients: effect of bariatric surgery. In Vivo 2016; 30: 321–330.

46. Zhang H, DiBaise JK, Zuccolo A et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 2009; 106: 2365–2370.
prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin Nutr 2015; 34: 845–858.
85. Wu GD, Chen J, Hoffmann C et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105–108.
86. Ridaura VK, Faith JJ, Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341: 1241214.
87. Le Roy T, Llopis M, Lepage P et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62: 1787–1794.
88. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913–6.e7.
89. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014; 12: 661–672.
90. Gagnière J, Raisch J, Veziant J et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016; 22: 501–518.
91. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer 2013; 13: 800–812.
92. Russel R, Gratz SW, Duncan SH et al. High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 2011; 93: 1062–1072.